Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors

Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors

IntroductionCardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting.MethodsTo investigate this issue, we conducted a...

Full description

Bibliographic Details
Main Authors: Lukas J. Motloch, Peter Jirak, Moritz Mirna, Lukas Fiedler, Paruir A. Davtyan, Irina A. Lakman, Diana F. Gareeva, Anton V. Tyurin, Ruslan M. Gumerov, Simon T. Matskeplishvili, Valentin N. Pavlov, Benzhi Cai, Kristen Kopp, Albert Topf, Uta C. Hoppe, Rudin Pistulli, Naufal S. Zagidullin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
COVID-19
long COVID-19
direct anticoagulation
dipyridamole
cardiovascular disease in COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.916156/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.916156/full

Similar Items